StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
SUPNBullishCorporate Developmentsnews
Medium materiality6/10

SUPN Secures Seven-Year Orphan Exclusivity for ONAPGO; Second Supplier Filing Ahead

Oct 21, 2026, 7:51 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Orphan exclusivity typically protects a product from generic competition, supporting revenue visibility; combined with a potential additional supplier, it could lift pricing power and stabilize supply, a favorable mix shift for SUPN's ONAPGO franchise.

AI summary

What happened, with direct paths to the underlying reporting

Supernus announced that the FDA has granted seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) in adults with advanced Parkinson's disease. The company also submitted an sNDA for a second ONAPGO supplier, with potential FDA approval by mid-2027. These developments could extend ONAPGO's revenue runway and improve supply reliability, supporting pricing power and broader adoption search.

  • FDA recognizes seven-year orphan exclusivity for ONAPGO in adults.
  • SUPN filed an sNDA for a second ONAPGO supplier; decision by mid-2027.
  • Exclusivity could extend ONAPGO's revenue window and protect pricing.
  • Second-supplier approval may improve supply reliability and uptake.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event